Reported effects are generally mild injection-site reactions, fatigue, lightheadedness after a dose
PMID 16551208
It works by restoring the biological signaling that illness, inflammation, and cellular dysfunction have disrupted which is precisely the goal in long COVID recovery
While specific results for the combination are still an area of active research, existing preclinical data support the rationale for studying these peptides together in controlled experimental systems
The GLP-1 drugs are the latest class to show a benefit in patients, this time with OSA, but like other tools have nontrivial side effects, cost concerns, and patient persistence issues that balance out the headline benefits. The size of the underlying patient populations, which are expected to surpass 1.3 billion globally by 2050, as well as the under penetration of CPAP treatment, which Andrew ballparks at 15% or less in many markets, reinforces the analysts argument
F.GaoH.et al (2021)
